Edition:
United States

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

1.67USD
3:59pm EST
Change (% chg)

$0.14 (+8.77%)
Prev Close
$1.54
Open
$1.55
Day's High
$1.68
Day's Low
$1.54
Volume
180,095
Avg. Vol
114,719
52-wk High
$3.78
52-wk Low
$1.09

Chart for

About

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer... (more)

Overall

Beta: --
Market Cap(Mil.): $35.55
Shares Outstanding(Mil.): 23.08
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.80 16.52
EPS (TTM): -- -- --
ROI: -- -0.65 36.19
ROE: -- -3.21 17.38

BRIEF-Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression

* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT

Feb 13 2018

BRIEF-Catabasis Pharmaceuticals reports third quarter financial results

* Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress

Nov 09 2017

BRIEF-Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease

* Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018

Oct 04 2017

Earnings vs. Estimates